{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T12:46:10Z","timestamp":1789908370064,"version":"4.0.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,2,16]],"date-time":"2018-02-16T00:00:00Z","timestamp":1518739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,2,16]],"date-time":"2018-02-16T00:00:00Z","timestamp":1518739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Baseline resistance-associated substitutions (RASs) have variable impacts in clinical trials but their prevalence and impact in real-world patients remains unclear. We performed baseline resistance testing using a commercial assay (10% cutoff) for 486 patients treated with LDV\/SOF or SMV\/SOF, with or without ribavirin, in the multi-center, observational HCV-TARGET cohort. Linkage of RASs was evaluated in selected samples using a novel quantitative single variant sequencing assay. Our results showed that the prevalence of NS3, NS5A, NS5B RASs was 45%, 13%, and 8%, respectively, and 10% of patients harbored RASs in 2 or more drug classes. Baseline LDV RASs in GT1a, TE, and cirrhosis LDV\/SOF subgroup was associated with 2\u20134% lower SVR12 rates. SMV RASs was associated with lower SVR12 rates in GT1a, treatment-experienced, cirrhotics SMV\/SOF subgroup. Pooled analysis of all patients with baseline RASs revealed that SVR12 was 100% (19\/19) in patients treated for longer than 98 days but was 87% (81\/93) in patients treated for shorter than 98 days. These results demonstrate that RASs prevalence and their impact in real world practice are in general agreement with registration trials, and suggest that longer treatment duration may overcome the negative impact of baseline RASs on SVR12 rates in clinical practice.<\/jats:p>","DOI":"10.1038\/s41598-018-21303-2","type":"journal-article","created":{"date-parts":[[2018,2,12]],"date-time":"2018-02-12T16:15:06Z","timestamp":1518452106000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir\/sofosbuvir or simeprevir\/sofosbuvir against GT1 HCV infection"],"prefix":"10.1038","volume":"8","author":[{"given":"Gary P.","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norah","family":"Terrault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline D.","family":"Reeves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph K.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Morelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josh","family":"Levitsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth E.","family":"Sherman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn M.","family":"Frazier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ananthakrishnan","family":"Ramani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joy","family":"Peter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Akuskevich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Fried","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,16]]},"reference":[{"key":"21303_CR1","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","volume":"2","author":"HCV Polaris Observatory","year":"2017","unstructured":"Polaris Observatory, H. C. V. et al. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol. Hepatol. 2, 161\u2013176 (2017).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"21303_CR2","unstructured":"WHO. Global Hepatitis Report 2017 (2017)."},{"key":"21303_CR3","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1056\/NEJM199908193410802","volume":"341","author":"MJ Alter","year":"1999","unstructured":"Alter, M. J. et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N. Engl. J. Med. 341, 556\u2013562 (1999).","journal-title":"N. Engl. J. Med."},{"key":"21303_CR4","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1002\/hep.22759","volume":"49","author":"MG Ghany","year":"2009","unstructured":"Ghany, M. G., Strader, D. B., Thomas, D. L. & Seeff, L. B. & American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 49, 1335\u20131374 (2009).","journal-title":"Hepatology"},{"key":"21303_CR5","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1053\/j.gastro.2009.09.067","volume":"138","author":"GL Davis","year":"2010","unstructured":"Davis, G. L., Alter, M. J., El-Serag, H., Poynard, T. & Jennings, L. W. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 138, e1\u20136 (2010). 513-21, 521.","journal-title":"Gastroenterology"},{"key":"21303_CR6","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","volume":"370","author":"N Afdhal","year":"2014","unstructured":"Afdhal, N. et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N. Engl. J. Med. 370, 1889\u20131898 (2014).","journal-title":"N. Engl. J. Med."},{"key":"21303_CR7","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","volume":"370","author":"N Afdhal","year":"2014","unstructured":"Afdhal, N. et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N. Engl. J. Med. 370, 1483\u20131493 (2014).","journal-title":"N. Engl. J. Med."},{"key":"21303_CR8","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa1501315","volume":"373","author":"S Naggie","year":"2015","unstructured":"Naggie, S. et al. Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1. N. Engl. J. Med. 373, 705\u2013713 (2015).","journal-title":"N. Engl. J. Med."},{"key":"21303_CR9","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1056\/NEJMoa1613512","volume":"376","author":"M Bourliere","year":"2017","unstructured":"Bourliere, M. et al. Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection. N. Engl. J. Med. 376, 2134\u20132146 (2017).","journal-title":"N. Engl. J. Med."},{"key":"21303_CR10","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","volume":"373","author":"JJ Feld","year":"2015","unstructured":"Feld, J. J. et al. Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. N. Engl. J. Med. 373, 2599\u20132607 (2015).","journal-title":"N. Engl. J. Med."},{"key":"21303_CR11","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1016\/S0140-6736(14)61036-9","volume":"384","author":"E Lawitz","year":"2014","unstructured":"Lawitz, E. et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 384, 1756\u20131765 (2014).","journal-title":"Lancet"},{"key":"21303_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7326\/M15-0785","volume":"163","author":"S Zeuzem","year":"2015","unstructured":"Zeuzem, S. et al. Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial. Ann. Intern. Med. 163, 1\u201313 (2015).","journal-title":"Ann. Intern. Med."},{"key":"21303_CR13","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1056\/NEJMoa1702417","volume":"378","author":"S Zeuzem","year":"2018","unstructured":"Zeuzem, S. et al. Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection. N. Engl. J. Med. 378, 354\u2013369 (2018).","journal-title":"N. Engl. J. Med."},{"key":"21303_CR14","doi-asserted-by":"publisher","first-page":"6716","DOI":"10.3390\/v7122968","volume":"7","author":"A Ahmed","year":"2015","unstructured":"Ahmed, A. & Felmlee, D. J. Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals. Viruses 7, 6716\u20136729 (2015).","journal-title":"Viruses"},{"key":"21303_CR15","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.jhep.2017.01.007","volume":"66","author":"S Zeuzem","year":"2017","unstructured":"Zeuzem, S. et al. NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcome. J. Hepatol. 66, 910\u2013918 (2017).","journal-title":"J. Hepatol."},{"key":"21303_CR16","doi-asserted-by":"publisher","first-page":"5915","DOI":"10.1128\/JVI.05959-11","volume":"86","author":"S Munshaw","year":"2012","unstructured":"Liu, L., Nardo, D., Li, E. & Wang, G. P. CD4 + T cell recovery with suppressive ART induced rapid sequence evolution in hepatitis C virus envelope but not NS3. AIDS 30, 691\u2013700 (2016).","journal-title":"J. Virol."},{"key":"21303_CR17","doi-asserted-by":"publisher","first-page":"5915","DOI":"10.1128\/JVI.05959-11","volume":"86","author":"S Munshaw","year":"2012","unstructured":"Munshaw, S. et al. Computational reconstruction of Bole1a, a representative synthetic hepatitis C virus subtype 1a genome. J. Virol. 86, 5915\u20135921 (2012).","journal-title":"J. Virol."},{"key":"21303_CR18","unstructured":"Jacobson, I. M. et al. Prevalence and Impact of Baseline NS5A Resistance-Associated Variants (RAVs) on the Efficacy of Elbasvir\/Grazoprevir (EBR\/GZR) Against GT1a Infection - 16 Weeks vs 12 weeks (AASLD 2016)."},{"key":"21303_CR19","first-page":"120","volume":"15","author":"T Leitner","year":"1993","unstructured":"Leitner, T. et al. Analysis of heterogeneous viral populations by direct DNA sequencing. BioTechniques 15, 120\u2013127 (1993).","journal-title":"BioTechniques"},{"key":"21303_CR20","doi-asserted-by":"publisher","first-page":"e69698","DOI":"10.1371\/journal.pone.0069698","volume":"8","author":"ME Kirst","year":"2013","unstructured":"Kirst, M. E. et al. Deep sequencing analysis of HCV NS3 resistance-associated variants and mutation linkage in liver transplant recipients. PloS one 8, e69698 (2013).","journal-title":"PloS one"},{"key":"21303_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/srep20310","volume":"6","author":"ZW Chen","year":"2016","unstructured":"Chen, Z. W., Li, H., Ren, H. & Hu, P. Global prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): mining the GenBank HCV genome data. Sci. Rep. 6, 20310 (2016).","journal-title":"Sci. Rep."},{"key":"21303_CR22","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1128\/AAC.02776-15","volume":"60","author":"JA Patino-Galindo","year":"2016","unstructured":"Patino-Galindo, J. A., Salvatierra, K., Gonzalez-Candelas, F. & Lopez-Labrador, F. X. Comprehensive Screening for Naturally Occurring Hepatitis C Virus Resistance to Direct-Acting Antivirals in the NS3, NS5A, and NS5B Genes in Worldwide Isolates of Viral Genotypes 1 to 6. Antimicrob. Agents Chemother. 60, 2402\u20132416 (2016).","journal-title":"Antimicrob. Agents Chemother."},{"key":"21303_CR23","doi-asserted-by":"publisher","first-page":"e0134395","DOI":"10.1371\/journal.pone.0134395","volume":"10","author":"J Dietz","year":"2015","unstructured":"Dietz, J. et al. Consideration of Viral Resistance for Optimization of Direct Antiviral Therapy of Hepatitis C Virus Genotype 1-Infected Patients. PLoS One 10, e0134395 (2015).","journal-title":"PLoS One"},{"key":"21303_CR24","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1053\/j.gastro.2016.06.002","volume":"151","author":"C Sarrazin","year":"2016","unstructured":"Sarrazin, C. et al. Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir. Gastroenterology 151, 501\u2013512.e1 (2016).","journal-title":"Gastroenterology"},{"key":"21303_CR25","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1002\/hep.27934","volume":"62","author":"E Lontok","year":"2015","unstructured":"Lontok, E. et al. Hepatitis C virus drug resistance-associated substitutions: State of the art summary. Hepatology 62, 1623\u20131632 (2015).","journal-title":"Hepatology"},{"issue":"S1","key":"21303_CR26","first-page":"1134A","volume":"60","author":"P Krishnan","year":"2014","unstructured":"Krishnan, P., Tripathi, R., Schnell, G., Reisch, T. & Beyer, J. Pooled analysis of resistance in patients treated with ombitasvir\/ABT-450\/r and dasabuvir with or without ribavirin in phase 2 and phase 3 clinical trials. Hepatology (Baltimore, Md.) 60(S1), 1134A\u20131135A (2014).","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"21303_CR27","doi-asserted-by":"publisher","first-page":"186-015","DOI":"10.1186\/s12985-015-0414-1","volume":"12","author":"A Costantino","year":"2015","unstructured":"Costantino, A. et al. Naturally occurring mutations associated with resistance to HCV NS5B polymerase and NS3 protease inhibitors in treatment-naive patients with chronic hepatitis C. Virol. J. 12, 186-015\u20130414-1 (2015).","journal-title":"Virol. J."},{"key":"21303_CR28","doi-asserted-by":"publisher","first-page":"e0157438","DOI":"10.1371\/journal.pone.0157438","volume":"11","author":"K Zhou","year":"2016","unstructured":"Zhou, K. et al. Natural Polymorphisms Conferring Resistance to HCV Protease and Polymerase Inhibitors in Treatment-Naive HIV\/HCV Co-Infected Patients in China. PLoS One 11, e0157438 (2016).","journal-title":"PLoS One"},{"key":"21303_CR29","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1128\/AAC.01452-09","volume":"54","author":"O Lenz","year":"2010","unstructured":"Lenz, O. et al. In vitro resistance profile of the hepatitis C virus NS3\/4A protease inhibitor TMC43. 5. Antimicrob. Agents Chemother. 54, 1878\u20131887 (2010).","journal-title":"5. Antimicrob. Agents Chemother."},{"key":"21303_CR30","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1002\/hep.28422","volume":"64","author":"E Lawitz","year":"2016","unstructured":"Lawitz, E. et al. Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2). Hepatology 64, 360\u2013369 (2016).","journal-title":"Hepatology"},{"key":"21303_CR31","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1053\/j.gastro.2016.08.004","volume":"151","author":"NA Terrault","year":"2016","unstructured":"Terrault, N. A. et al. Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response. Gastroenterology 151, 1131\u20131140.e5 (2016).","journal-title":"Gastroenterology"},{"key":"21303_CR32","doi-asserted-by":"publisher","first-page":"20166","DOI":"10.1073\/pnas.1110064108","volume":"108","author":"CB Jabara","year":"2011","unstructured":"Jabara, C. B., Jones, C. D., Roach, J., Anderson, J. A. & Swanstrom, R. Accurate sampling and deep sequencing of the HIV-1 protease gene using a Primer ID. Proc. Natl. Acad. Sci. USA 108, 20166\u201320171 (2011).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"21303_CR33","doi-asserted-by":"publisher","first-page":"6079","DOI":"10.1128\/AAC.03466-14","volume":"58","author":"CB Jabara","year":"2014","unstructured":"Jabara, C. B. et al. Hepatitis C Virus (HCV) NS3 sequence diversity and antiviral resistance-associated variant frequency in HCV\/HIV coinfection. Antimicrob. Agents Chemother. 58, 6079\u20136092 (2014).","journal-title":"Antimicrob. Agents Chemother."},{"key":"21303_CR34","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu. EASL Recommendations on Treatment of Hepatitis C 2016. J. Hepatol. 66, 153\u2013194 (2017).","DOI":"10.1016\/j.jhep.2016.09.001"},{"key":"21303_CR35","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1002\/hep.29258","volume":"66","author":"V Saxena","year":"2017","unstructured":"Saxena, V. et al. Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV-TARGET study. Hepatology 66, 1090\u20131101 (2017).","journal-title":"Hepatology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-21303-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-21303-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-21303-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T02:37:07Z","timestamp":1671590227000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-21303-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,16]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["21303"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-21303-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,16]]},"assertion":[{"value":"8 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"GPW discloses research grant funding from the NIH, Department of Defense, Ocean Spray Cranberries, and Abbvie. NT discloses institutional grant funding from Gilead, BMS, AbbVie, NIH, and Merck; consultant work for Gilead and Merck; lectures for CCO Hepatitis, Practice Point Communications, Focus Medical Communications, and Annenberg Center for Health Sciences, PRIME Education Inc. JDR discloses stock from laboratory Corporation of America Holdings, along with employment at Monogram Biosciences and Laboratory Corporation of America Holdings. LL has nothing to disclose. EL has nothing to disclose. LZ has nothing to disclose. JKL discloses institutional grant funding from BMS, Genfit, Gilead, Hologic, Intercept, and Prometheus (all to institution) along with consultant work for AbbVie, BMS, & Gilead. GM discloses institutional grant funding from AbbVie, BMS, Gilead, Merck, Janssen, Vertex, Idenix, Conatus, and Salix. AK discloses institutional grant funding from Gilead along with lecturing for Gilead. JL discloses institutional grant funding from Novartis along with lectures Gilead and Novartis, along with stock in Transplant Genomics Incorporated. KES discloses institutional grant funding from AbbVie, BMS, Gilead, Innovio, Merck, and MedImmune along with consultant work for Medimmune and Viiv; Royalties from U.S. Army and UpToDate; other disclosures from DSMB: MedPlace and SynteractHCR. LMF discloses institutional grant funding and consultant work from Gilead, AbbVie, Janssen, and Merck. AR discloses sponsored lectures from Gilead Sciences and Allergan. JP has nothing to disclose. LA has nothing to disclose. MWF discloses institutional grant funding from Abbvie, Bristol Myers Squibb, Gilead, and Merck along with consultant work for Abbvie, Bristol Myers Squibb, Gilead, Merck, and TARGET PharmaSolutions. MWF also discloses stockholding from TARGET PharmaSolutions and other disclosures from Research grants from NIH. DRN discloses institutional grant funding from AbbVie, Gilead, BMS, Janssen, and Merck along with stockholding from TARGET PharmaSolutions.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"3199"}}